As the global market for obesity and diabetes treatments expands faster than expected, market attention is focusing on D&D Pharmatek, which is developing an oral peptide drug delivery platform. The context is that Eli Lilly's upward revision of its annual sales forecast, driven by strong sales of Mounjaro and Zepbound, has reaffirmed the growth potential of the obesity treatment industry.

■ Eli Lilly Raises 2026 Annual Sales Forecast to $85–87 Billion

Eli Lilly announced that its second-quarter 2026 revenue reached $22.974 billion, a 48% increase year-over-year. During the same period, net income totaled $7.1 billion, with adjusted earnings per share coming in at $8.38. Reflecting the expansion in sales driven primarily by its obesity and diabetes treatments, the company raised its 2026 full-year revenue guidance from the previous range of $82–85 billion to $85–87 billion.

The key products driving the earnings growth are the GLP-1 class diabetes drug Mounjaro and the obesity drug Zepbound. Second-quarter global sales of Mounjaro surged 91% year-over-year to $9.943 billion, with U.S. sales at $4.8 billion and non-U.S. sales at $5.2 billion. Zepbound's revenue also grew 46% to $4.928 billion. The combined quarterly revenue from these two products alone reached approximately $14.871 billion.

■ D&D Pharmatek's 'OralLink'… Transforming Injections into Pills

D&D Pharmatek possesses an oral drug delivery platform called 'OralLink,' designed to deliver peptide drugs in oral form. Peptide compounds are known to be easily degraded in the gastrointestinal tract and have low absorption rates, making the development of oral formulations highly challenging. OralLink aims to overcome these limitations by developing GLP-1 class substances, which are currently administered via injection, into pill form.

■ "No Direct Linkage… Need to Distinguish Between Expectations and Verification"

However, it is important to note in the market that the expansion of Eli Lilly's Mounjaro and Zepbound sales does not directly translate into D&D Pharmatek's earnings. Based on currently available information, it is difficult to confirm any direct technology transfer or co-development agreement between the two companies. Eli Lilly's strong performance serves as an industry indicator demonstrating the scale of the GLP-1 market and the business viability of oral follow-on products, rather than being a direct revenue driver for D&D Pharmatek.

With Eli Lilly raising its annual revenue forecast to up to $87 billion and Mounjaro recording approximately $10 billion in quarterly sales, the growth trajectory of the obesity treatment market has been reaffirmed once again. While the expansion of the global market could present opportunities for D&D Pharmatek, actual performance must be proven through clinical results and commercialization agreements, requiring an approach that distinguishes between expectations and verification.

[※ This article is general information based on publicly available corporate announcements and disclosures and does not recommend the purchase or sale of any specific stock. Clinical trials may be halted during the development process or yield changed results, and investment decisions and their associated responsibilities lie solely with the investor. This article was written with AI assistance.]